Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Rating of “Hold” by Brokerages

Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) has received an average recommendation of “Hold” from the eight ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $4.00.

A number of equities analysts have recently commented on the stock. Zacks Research raised shares of Mereo BioPharma Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mereo BioPharma Group in a report on Thursday, January 22nd. Robert W. Baird set a $1.00 price target on Mereo BioPharma Group in a report on Monday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mereo BioPharma Group in a research report on Monday, December 29th. Finally, Lifesci Capital lowered Mereo BioPharma Group from an “outperform” rating to a “hold” rating in a research report on Monday, December 29th.

Mereo BioPharma Group Price Performance

Shares of MREO opened at $0.41 on Wednesday. The business’s 50-day moving average is $1.08 and its 200-day moving average is $1.56. The company has a market capitalization of $65.24 million, a price-to-earnings ratio of -6.83 and a beta of 0.37. Mereo BioPharma Group has a fifty-two week low of $0.20 and a fifty-two week high of $3.05.

Mereo BioPharma Group (NASDAQ:MREO) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.01) EPS for the quarter. Equities research analysts expect that Mereo BioPharma Group will post -0.03 earnings per share for the current fiscal year.

Trending Headlines about Mereo BioPharma Group

Here are the key news stories impacting Mereo BioPharma Group this week:

• Neutral Sentiment: Lead‑plaintiff deadline and procedural notices: Multiple firms remind investors of the April 6, 2026 deadline to move to be lead plaintiff in the federal securities class action covering purchases from June 5, 2023 through December 26, 2025 — a procedural development investors should note for potential recovery timelines. Rosen Law Firm notice
• Negative Sentiment: Sharp rise in short interest: As of Jan. 30 short interest totaled 13,042,775 shares — up 32.9% from Jan. 15 — representing roughly 8.7% of shares outstanding and a short‑interest ratio of ~1.5 days (using reported average volume). Rising shorts signal increased bearish positioning and can amplify downside if negative news continues. (Entry: short‑interest data)
• Negative Sentiment: Multiple class‑action filings and solicitations: Several national law firms have filed or publicized actions alleging securities law violations and are soliciting lead‑plaintiffs (claims covering June 5, 2023–Dec 26, 2025). Firms include Bronstein, Rosen, Schall, Robbins, Faruqi & Faruqi, Berger Montague, DJS and others — amplification of litigation coverage increases headline risk and potential future liability. Bronstein notice Schall Law Firm notice Robbins LLP notice

Institutional Trading of Mereo BioPharma Group

A number of institutional investors have recently modified their holdings of MREO. Goldman Sachs Group Inc. boosted its position in Mereo BioPharma Group by 0.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company’s stock worth $4,783,000 after purchasing an additional 6,068 shares during the period. Squarepoint Ops LLC grew its position in shares of Mereo BioPharma Group by 45.4% during the 3rd quarter. Squarepoint Ops LLC now owns 30,055 shares of the company’s stock worth $62,000 after purchasing an additional 9,387 shares in the last quarter. Marex Group plc bought a new position in shares of Mereo BioPharma Group during the second quarter worth approximately $27,000. Forefront Analytics LLC boosted its stake in shares of Mereo BioPharma Group by 73.4% in the third quarter. Forefront Analytics LLC now owns 33,180 shares of the company’s stock valued at $68,000 after buying an additional 14,042 shares during the period. Finally, State of New Jersey Common Pension Fund D acquired a new stake in Mereo BioPharma Group during the third quarter worth approximately $32,000. 62.83% of the stock is currently owned by institutional investors.

About Mereo BioPharma Group

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.